POLE Mutation Screening for Immunotherapy Response Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatment methods, particularly immunotherapy, have limited effectiveness and high costs, and there is a need for methods to identify patients with tumors that are likely to respond to immunotherapy and those harboring a 'high mutator phenotype' related to POLE mutations, which could benefit from specific treatment modalities.
Innovation Solution
A method involving the comparison of nucleotide sequences of the DNA polymerase epsilon (POLE) gene from cancerous tumors with control samples to detect mutations, indicating a high mutator phenotype, which predicts responsiveness to immunotherapeutic treatments, and a kit using oligonucleotides to detect these mutations for guiding treatment decisions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunotherapy is administered to cancer patients, then immune system stimulation and potential tumor response occur, but treatment cost increases significantly and response rate remains low
Solution Approach 1:
The patent applies preliminary action by performing POLE mutation screening before immunotherapy administration. This pre-treatment genetic testing identifies patients with high mutator phenotypes who are more likely to respond to immunotherapy, allowing clinicians to select appropriate candidates in advance and avoid administering expensive immunotherapy to patients unlikely to benefit, thereby improving overall treatment response rates while reducing unnecessary treatment costs
Solution Approach 2:
The patent utilizes the tumor's own genetic characteristics (POLE mutations creating high mutator phenotype) as a biomarker to predict treatment response. The tumor's inherent molecular profile serves as a self-indicating feature that guides treatment selection, eliminating the need for extensive trial-and-error treatment approaches and enabling more cost-effective, targeted immunotherapy deployment
2Measurement precision
If POLE mutation screening is performed to identify high mutator phenotype patients, then treatment selection accuracy improves, but diagnostic complexity and testing requirements increase
Solution Approach 1:
The patent extracts and focuses specifically on the POLE gene as a single key biomarker for predicting immunotherapy response. By isolating this particular genetic element from the complex genome and using it as the primary screening target, the method achieves high patient selection accuracy while avoiding the need for comprehensive genomic sequencing or multiple biomarker assessments, thereby simplifying the overall diagnostic approach
Solution Approach 2:
The patent applies local quality by concentrating diagnostic efforts on a specific gene (POLE) with known clinical significance rather than performing broad, uniform genetic screening across the entire genome. This targeted approach assigns different levels of diagnostic intensity to different genomic regions, achieving precise patient stratification with reduced testing complexity compared to whole-genome approaches
Data Source
AI summary
The invention includes a method of determining whether a mammal's cancerous tumor is associated with a hypermutator phenotype (i.e., harboring a large number of mutations) for the DNA Polymerase epsilon (POLE) gene as compared to normal cells. The invention further includes a method of selecting patients harboring an immunogenic tumor that is responsive to immunotherapy.